Novo Nordisk A/s

This study looked at the long-term safety and effectiveness of Ozempic in over 3,200 Japanese adults with type 2 diabetes. Participants took the drug as prescribed by their doctor for about 3 years. Researchers tracked side effects, blood sugar levels, and weight changes to see h…

This study tested a new medicine, NNC0487-0111, in 448 adults with type 2 diabetes to see how well it lowers blood sugar and body weight. Participants received either a weekly injection, a daily pill, or a placebo for about 43 weeks. The goal is to find the best dose for controll…

This study tested a new once-a-week medicine called IcoSema, which combines insulin and semaglutide, against another once-a-week insulin in people with type 2 diabetes whose blood sugar was not well controlled with daily insulin. About 1,291 adults took part for a year. The goal …

This study looked at how well the once-daily pill Rybelsus works for adults with type 2 diabetes in the UK. Over 300 people took the medication as prescribed by their doctor and filled out questionnaires about their treatment. The main goal was to see if the pill helped lower blo…

This study tested a new medicine (NNC0480-0389) combined with semaglutide, an already approved diabetes drug, in 500 adults with type 2 diabetes. The goal was to see how well different doses lower blood sugar and to pick the best doses for future studies. Participants gave themse…

This study tested a weekly injection of semaglutide (2.4 mg) in 242 adults who were overweight or had obesity. Participants received either the drug or a placebo for about 44 weeks. The main goals were to see how much weight people lost and how many lost at least 5% of their body…

This study tested a new insulin called icodec that is injected just once a week, compared to a standard daily insulin (degludec), in 582 adults with type 1 diabetes. Both groups also used mealtime insulin. The goal was to see if the weekly insulin controls blood sugar as well as …

This early-stage study tested a new medicine, NNC0519-0130, given as a weekly injection to help people with obesity or type 2 diabetes. The main goals were to check for side effects and measure how the drug moves through the body. 82 participants were randomly assigned to get eit…

This study tested a new investigational medicine called CagriSema in 274 adults with type 2 diabetes who were already taking daily insulin. The goal was to see if CagriSema could lower blood sugar and body weight more than a placebo. Participants received either CagriSema or a du…

This study tested a new oral medicine called NDec in 96 adults with sickle cell disease. The goal was to see if it safely raises hemoglobin levels and reduces painful crises. Participants took capsules twice weekly for about a year, with some also continuing their usual hydroxyur…

This study tested a new insulin called icodec that is injected just once a week, compared to a standard daily insulin (glargine), in 429 adults with type 2 diabetes. Participants received either the weekly or daily insulin for 6 months. The main goal was to see if the weekly insu…

This study tested a new experimental medicine called CagriSema (a combination of cagrilintide and semaglutide) against the approved drug tirzepatide for weight loss in 809 adults with obesity. Participants received weekly injections under the skin, with doses gradually increased.…

This study followed 187 adults with type 2 diabetes in Mexico who were prescribed oral semaglutide (Rybelsus®) by their doctors. The goal was to see how well the once-daily pill lowers blood sugar and affects body weight over 8-10 months. Participants completed questionnaires abo…

This study tested a new investigational medicine called CagriSema in 189 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. Participants received either CagriSema or a placebo injection once a week for about a year. The main goal was…

This study looked at whether semaglutide, a type 2 diabetes medicine, can reduce the risk of major heart problems like heart attacks, strokes, or heart-related death. About 9,600 adults with type 2 diabetes and existing heart disease took either semaglutide tablets or a placebo d…

This study tested a new once-weekly growth hormone injection (NNC0195-0092) against the standard daily growth hormone shot in 76 children with growth hormone deficiency who had never been treated before. The goal was to see if the weekly shot worked as well for helping kids grow …

This study tested a new medicine called CagriSema (a mix of two drugs) in 331 East Asian adults with obesity or overweight. Participants received a weekly injection for about 1.5 years. The main goal was to see how much weight they lost compared to another drug. The study is comp…

This study looked at how safe it is for people with hemophilia A to switch from their current medicine (emicizumab) to a new one called Mim8. Mim8 helps prevent bleeding episodes by doing the job of the missing clotting factor. The study included 61 adults and teens who received …

This study collected information on how the once-daily pill Rybelsus (oral semaglutide) works in adults with type 2 diabetes. Researchers tracked changes in blood sugar levels and body weight over 8-10 months. The goal was to see how well the medication controls diabetes in every…

This study tested a new insulin that is injected just once a week against a standard daily insulin in 582 adults with type 2 diabetes. The goal was to see if the weekly insulin controls blood sugar as well as the daily one. Participants also used mealtime insulin as needed. The t…

This study tested a new medicine, somapacitan, given once a week, against the standard daily Norditropin in 200 children with growth hormone deficiency. The goal was to see if the weekly shot works as well and is safe. Children received either treatment by chance, and both doctor…

This study followed 650 adults with type 2 diabetes in Japan who were prescribed oral semaglutide (Rybelsus) by their doctors. The goal was to see how well the medication lowers blood sugar and what side effects occur in everyday use. Participants took the pill once daily and com…

This study looked at how well the once-daily pill Rybelsus® (oral semaglutide) works for adults with type 2 diabetes in Spain. Researchers tracked changes in blood sugar levels, body weight, and how satisfied patients were with their treatment over 8-10 months. The goal was to se…

This study tested a new insulin called icodec that is injected just once a week, compared to standard insulins taken every day. Over 1,000 adults with type 2 diabetes who had never used insulin before took part. The goal was to see if the weekly insulin controls blood sugar just …

This study looked at how well oral semaglutide works for Thai adults with type 2 diabetes. Researchers reviewed medical records of 209 patients to see changes in blood sugar and body weight over 6 to 12 months. The goal was to understand if this daily pill helps manage diabetes e…

This study tested a new fast-acting insulin (faster aspart) against a standard insulin (NovoRapid) in 331 adults with type 1 or type 2 diabetes. Participants took either insulin four times daily along with a long-acting insulin, with or without metformin. The main goal was to see…

This study tested a new weekly injection called CagriSema (a mix of two medicines) to help Chinese adults with obesity or overweight lose weight. About 300 participants received either CagriSema, a placebo (dummy shot), or semaglutide alone for around one year. The main goal was …

This study tested a once-weekly injection of semaglutide (2.4 mg) to help people with overweight or obesity lose weight. About 375 adults took part, some receiving the drug and others a placebo, along with lifestyle advice. The main goal was to see how much weight they lost over …

This study tested whether oral semaglutide, a drug already used for diabetes, can slow the progression of early Alzheimer's disease. About 1,840 people with mild cognitive impairment or mild dementia took either the drug or a placebo for up to 3 years and 4 months. Researchers me…

This early-stage study tested a new medicine (NNC0487-0111) for weight control in 36 Chinese adults with overweight or obesity. The main goal was to see if the medicine is safe and how it moves through the body. Participants received either the study drug or a placebo by injectio…

This study looked at whether a once-weekly medicine called semaglutide (used for weight loss and diabetes) can lower the risk of heart attacks, strokes, and death in people with overweight or obesity. Researchers analyzed medical records of over 285,000 people in the US. The goal…

This study tested how well semaglutide (Wegovy) helps people with obesity lose weight compared to four other approved weight loss medications. About 500 employees from three US companies took part. The goal was to see which drug works best for weight loss and improves quality of …

This study tested a weekly injection of semaglutide (2.4 mg) in 207 adults with obesity and prediabetes. Participants received either the drug or a placebo for 12 months, plus lifestyle advice. The goal was to see if the drug could help them lose weight and return blood sugar to …

This early-stage study tested a new medicine, NNC0519-0130, in 20 overweight or obese Chinese men. The goal was to see how the drug moves through the body and if it is safe. Participants received either the drug or a placebo for about 28 weeks. This is not a cure, but aims to hel…

This study tested a daily semaglutide tablet (50 mg) in 667 adults with overweight or obesity to see if it helps with weight loss. Participants took either the real pill or a placebo for 68 weeks, along with lifestyle advice. The main goals were measuring how much weight they los…

This study tested a new drug called NNC0487-0111, given as an injection under the skin, to see if it is safe and how it works in the body. It included 125 adults aged 18-55 who were overweight or obese. The goal was to help manage weight, but ongoing treatment may be needed.

This study tested whether higher daily doses (25 mg and 50 mg) of the oral diabetes medication semaglutide (Rybelsus®) work better than the standard 14 mg dose in adults with type 2 diabetes. About 1,600 participants took one tablet daily for 68 weeks, with doses gradually increa…

This study tested whether combining a new liver medicine (NNC0194-0499) with semaglutide (a diabetes and weight-loss drug) can reduce liver scarring in people with non-alcoholic steatohepatitis (NASH). About 698 adults received weekly injections of either the combo, a placebo, or…

This study looked at how well the once-daily pill Rybelsus® works for adults with type 2 diabetes in Saudi Arabia. Researchers tracked changes in blood sugar and body weight over 8-10 months. Participants took the medication as prescribed by their doctor and filled out a question…

This study tested whether a new medicine called CagriSema (a combination of two drugs) can reduce kidney damage in people with chronic kidney disease, type 2 diabetes, and overweight or obesity. About 626 participants received either CagriSema, one of the two drugs alone, or a pl…

This study tested a new weekly injection called CagriSema, which combines two medicines (semaglutide and cagrilintide), in over 2,700 adults with type 2 diabetes. Participants took CagriSema, one of the single medicines, or a placebo, along with their usual diabetes pills. The go…

This study looked at how oral semaglutide (Rybelsus) helps control blood sugar in adults with type 2 diabetes. Researchers followed 458 people in Italy for about 8-10 months as they took the medication as prescribed by their doctor. The main goal was to see changes in blood sugar…

This study looked at the safety and effectiveness of Refixia, a medicine for Hemophilia B, when used in everyday medical care. 28 patients in Japan were followed over time. Researchers counted side effects and bleeding episodes to make sure the drug works well and is safe for lon…

This study tested whether adding a weekly semaglutide injection (a drug that helps control blood sugar and weight) to a lower dose of insulin works as well as a higher dose of insulin alone. About 573 adults with type 2 diabetes and overweight took part for around 11 months. The …

This study looked at whether using a smart insulin pen (NovoPen 6) with two insulins (Tresiba and Fiasp) helps people with type 1 diabetes achieve better blood sugar levels. About 411 adults took part for 9-11 months, using their own continuous glucose monitor and a mobile app to…

This study tested a drug called ziltivekimab in 36 people with advanced chronic kidney disease to see if it could reduce inflammation and lower heart disease risks. Participants received either a low dose, a high dose, or a placebo injection every 4 weeks for 3 doses. The main go…

This study tested a new medicine called Mim8 in 281 adults and teens with hemophilia A, including those whose bodies make antibodies that block standard treatment. Mim8 helps replace the missing clotting factor and is given as a weekly or monthly injection under the skin. The goa…

This study tested a drug called Ziltivekimab in 264 people with advanced chronic kidney disease and high inflammation. The goal was to see if the drug could lower inflammation markers and find the best dose for a future heart study. Participants received monthly injections of eit…

This study tested a new insulin called icodec that is injected just once a week, compared to a standard daily insulin (degludec), in 526 adults with type 2 diabetes. The goal was to see if the weekly insulin controls blood sugar as well as the daily one over 26 weeks. Participant…

This study tested a new medicine called CagriSema (a combination of two drugs) to help people with excess weight and type 2 diabetes lose weight. About 1,200 adults took part, receiving either CagriSema or a placebo once a week for around 1.5 years. The main goals were to measure…

This study tested a new fast-acting insulin (NNC0471-0119) given through an insulin pump in 43 adults with type 1 diabetes. Researchers measured how quickly the insulin entered the bloodstream and lowered blood sugar, comparing it to a standard insulin (insulin aspart). The goal …

This study tested three different doses of semaglutide (2 mg, 8 mg, and 16 mg) in 245 adults with type 2 diabetes and overweight who were already taking metformin. The main goals were to see how well each dose lowered blood sugar and body weight over 40 weeks. Participants receiv…

This small study tested an experimental drug called etavopivat in 12 children and young adults (ages 12-21) with sickle cell disease. The goal was to see if the drug could improve blood flow and oxygen delivery to the brain and muscles. Participants took the drug for a set period…

This study tested a new medicine called dasiglucagon against the standard glucagon for treating severe low blood sugar in Asian adults and Japanese teens with type 1 diabetes. About 38 participants received both drugs in random order to see if dasiglucagon raises blood sugar just…

This study looked at how safe and effective the prescription weight-loss drug Saxenda is for obese adults and teenagers in Taiwan. About 300 people took the medicine as part of their regular care for 26 weeks. The main goal was to track any side effects and see how well the drug …

This study tested a new investigational medicine called CagriSema, which combines two drugs (cagrilintide and semaglutide), in 158 adults with type 2 diabetes. Participants received either CagriSema, one of its components, or a placebo, all alongside their usual metformin. The go…

This study tested a new medicine called NNC0519-0130 to help people with excess body weight lose weight. About 354 adults aged 18-75 who had tried and failed to lose weight before took part. Participants received 1-2 injections under the skin once a week for up to 42 weeks, and r…

This study compares a once-daily pill called RYBELSUS® (oral semaglutide) to other diabetes pills in adults with type 2 diabetes who are already taking metformin. About 1,020 participants will be randomly assigned to receive either RYBELSUS® or another oral glucose-lowering medic…

This study tested whether taking two medicines together—cagrilintide and semaglutide—works better than either one alone for controlling blood sugar in people with type 2 diabetes. 92 adults with type 2 diabetes and a BMI of 27 or higher took part. The combination led to greater r…

This study tested a daily semaglutide tablet (25 mg) in 307 adults with overweight or obesity to see if it helps with weight loss. Participants took the pill or a placebo for 64 weeks, followed by 7 weeks of follow-up. The main goals were to measure the percentage of weight lost …

This study tested a long-acting clotting factor called N8-GP in 124 children under 6 with severe haemophilia A who had never received clotting factor treatment before. The goal was to see if it safely prevents and treats bleeding episodes. Results showed how many children develop…

This study tested a high dose (7.2 mg) of semaglutide, a once-weekly injection, in 1407 adults with obesity. Participants received either the high dose, a lower dose, or a placebo, plus lifestyle advice. The main goal was to measure weight loss over 72 weeks. Results showed that …

This study looked at how safe a new once-weekly insulin (insulin icodec) is during exercise and long periods without food in 30 adults with type 2 diabetes. Participants first took a daily insulin for a week, then switched to the weekly insulin for up to 14 weeks. The goal was to…

This study tested a once-weekly insulin shot (icodec) combined with a flash glucose monitor (a small sensor on the arm) in 51 adults with type 2 diabetes who had never used insulin before. The goal was to see if this approach could safely control blood sugar levels over 26 weeks.…

This study tested whether a new way of making the diabetes drug semaglutide works as well as the current version. 388 adults with type 2 diabetes received weekly injections for about 8 months. The main goal was to see if both versions control blood sugar levels equally well.

This study followed 99 adults with type 2 diabetes who were already prescribed oral semaglutide (Rybelsus) by their doctor. Researchers collected data from routine clinic visits and questionnaires over 8-10 months to see how well the medication controlled blood sugar and affected…

This early study tested a new medicine, NNC0519-0130, in 161 people to see if it is safe and how it works in the body. The medicine aims to lower blood sugar and reduce appetite, which could help people with type 2 diabetes and overweight. Participants received either the medicin…

This study tested a medicine called turoctocog alfa pegol (N8-GP) in 36 Chinese men with severe haemophilia A, a condition where blood doesn't clot properly. The medicine, already used in other countries, was given as a shot into a vein to treat and prevent bleeding episodes. The…

This study tested a high dose (7.2 mg) of the weekly injection semaglutide in 512 adults with obesity and type 2 diabetes. Participants received either the high dose, a lower dose, or a placebo, along with lifestyle counseling. The main goals were to measure weight loss and blood…

This study tested a new once-weekly medicine called IcoSema (a mix of two diabetes drugs) against daily insulin shots in 485 adults with type 2 diabetes whose blood sugar was not well controlled by pills. The goal was to see if the weekly shot works better at lowering blood sugar…

This study tested a new once-weekly injection called IcoSema (a mix of two diabetes drugs) against daily insulin in 679 adults with type 2 diabetes whose blood sugar was not well controlled with daily basal insulin. The goal was to see if the weekly shot works as well or better a…

This study tested a new daily pill (oral semaglutide) against a placebo in 132 children and teenagers with type 2 diabetes, all also taking metformin and/or insulin. The goal was to see if the pill improves blood sugar control and is safe for young people. Participants took one t…

This study looked at the safety and effectiveness of Xultophy, a combination insulin and GLP-1 medicine, in 750 adults with type 2 diabetes in Korea. Participants used the drug as their doctor prescribed during routine care for about 26 weeks. The goal was to track side effects a…

This study tested whether adding semaglutide (a GLP-1 drug) to a new once-weekly insulin (insulin icodec) helps people with type 2 diabetes who still have high blood sugar despite using daily insulin. 148 adults took part. First, everyone received weekly insulin icodec for 26 wee…

This study tested whether using a smartphone app (Ozempic app) and a device that attaches to the Ozempic injection pen helps people with type 2 diabetes continue their weekly medication. 304 participants were followed for about 10 months. The goal was to see if the app improves t…

This study looked at whether using a smartphone app called 'Dose Check' together with the insulin Tresiba helps people with type 2 diabetes control their blood sugar. About 179 adults in Saudi Arabia took part for 6-7 months. The goal was to see if the app helped them use the rig…

This study looked at how well the diabetes pill Rybelsus (oral semaglutide) works in real life for adults with type 2 diabetes in Sweden. Researchers tracked blood sugar levels and weight changes over 8-10 months in 194 people who were already prescribed the medication by their d…

This study tested whether adding a new medicine (NNC0165-1875) to the existing weight loss drug semaglutide helps people with obesity lose more weight. 120 adults with a BMI between 30 and 45 took part. Participants received either the new drug plus semaglutide or a placebo plus …

This study tested a new insulin called icodec that is injected just once a week, compared to a standard daily insulin (glargine), in 984 adults with type 2 diabetes who had never used insulin before. The goal was to see if the weekly insulin controls blood sugar as well as the da…

This study tested a new medicine called Mim8 for people with hemophilia A, a condition where blood doesn't clot properly. Mim8 is given as a shot under the skin to help prevent bleeding episodes. The trial included 275 healthy volunteers and people with hemophilia A, with or with…

This study followed 244 adults with type 2 diabetes in Japan who were already prescribed Xultophy by their doctor. Researchers tracked blood sugar levels and low blood sugar episodes over 26 weeks to see how well the treatment works in everyday life. The goal was to understand re…

This study tested whether a daily oral medication called semaglutide (a drug already used for diabetes) can slow down memory and thinking problems in people with early Alzheimer's disease. About 1,840 adults aged 55-85 with mild cognitive impairment or mild dementia took either t…

This study tracked 50 adults with type 2 diabetes in Finland who were already prescribed oral semaglutide (Rybelsus) by their doctor. The goal was to see how well the pill lowers blood sugar and affects body weight over 8-10 months. Participants filled out a questionnaire about h…

This study tested whether a weekly injection of semaglutide (2.4 mg) helps Asian adults with obesity (BMI 25 or higher) lose weight. About 150 participants received either the drug or a placebo for 44 weeks, along with diet and exercise advice. The main goal was to see how much w…

This study tracked 145 adults with type 2 diabetes in the Netherlands who were prescribed oral semaglutide (Rybelsus) by their doctors. Researchers measured changes in blood sugar levels and body weight over 8-10 months. Participants also filled out questionnaires about how they …

This study tested a new medicine called nonacog beta pegol (N9-GP) in 54 children under 6 years old with severe hemophilia B (a bleeding disorder). The goal was to see if the drug is safe and effective at preventing and treating bleeding episodes. The children received regular in…

This study looked at Fiasp®, a fast-acting mealtime insulin, in 42 adults with type 1 or type 2 diabetes. Doctors prescribed the insulin as usual, and researchers tracked side effects and blood sugar control for about 6 months. The goal was to see how well Fiasp® works and how sa…

This study looked at how quickly a fast-acting insulin (faster aspart) enters the blood in 23 Chinese adults with type 1 or type 2 diabetes. Participants received one injection of faster aspart and one of the standard insulin NovoRapid, in random order. Blood samples were taken o…

This study tested a weekly injection of semaglutide (a weight-loss medicine) in 201 teenagers aged 12 to 17 with overweight or obesity. Participants received either the drug or a dummy injection for about 15 months, plus lifestyle advice. The main goal was to see how much their b…

This study tested a drug called ziltivekimab in 24 Chinese adults with chronic kidney disease and signs of inflammation. Participants received either the drug or a placebo (dummy injection) three times over several weeks. The goal was to see how the drug moves through the body an…

This early-stage study tested a new medicine, NNC0363-1063, in 117 healthy volunteers and people with type 1 diabetes. The goal was to check safety, how the body processes the drug, and its effect on blood sugar. Results will help decide if further testing is warranted.

This study looked at how well the diabetes pill Rybelsus (oral semaglutide) works in everyday life for adults with type 2 diabetes in Canada. About 194 people took the medication as prescribed by their doctor and filled out questionnaires over 8-10 months. The main goal was to se…

This study tested a new investigational drug called CagriSema against the approved drug tirzepatide in over 1,000 adults with type 2 diabetes. Participants received weekly injections of either drug for up to 1.5 years. The goal was to see which treatment better lowers blood sugar…

This study tested a new medicine called CagriSema, which combines two drugs (cagrilintide and semaglutide), to help people with overweight or obesity lose weight. About 300 adults took part, receiving either CagriSema or a dummy shot once a week for around 1½ years. The main goal…

This study looked at how safe and tolerable a weekly injection of semaglutide (Ozempic) is for people with type 2 diabetes in Chile. 104 adults received the medicine for about 24 weeks. The goal was to track side effects and changes in blood sugar control, not to cure diabetes.

This study tested whether a daily semaglutide tablet helps Chinese adults with overweight or obesity lose weight. About 200 participants took either the drug or a placebo for 44 weeks, along with diet and exercise advice. The main goals were to measure the percentage of weight lo…

This study tested several drugs, alone or together, to see if they could reduce liver damage and alcohol use in people with alcohol-related liver disease. About 270 adults took part and received either a study drug or a placebo for around 39 weeks. The goal was to find treatments…

This study tested a medicine called nonacog beta pegol (N9-GP) in 30 Chinese men aged 12-70 with moderate to severe hemophilia B. The medicine helps blood clot and was given as an injection to treat or prevent bleeding episodes. The study lasted about 12-16 months and found that …

This early study tested a new medicine called NNC0519-0130 in 134 adults with overweight or obesity. Researchers compared four different ways of increasing the dose over time to see which caused fewer side effects. The study lasted about 24 weeks and focused on safety and tolerab…

This study looked at whether semaglutide, a medicine used for diabetes and weight loss, can reduce inflammation in the brain and body of people with early Alzheimer's disease. Twenty-three participants with mild memory problems or mild dementia received either semaglutide or a pl…

This study tested a new medicine, NNC0519-0130, given as a weekly injection to help people with type 2 diabetes lower blood sugar and body weight. About 299 adults took part, receiving one of seven different doses or a placebo for around 40 weeks. The goal was to find the best do…

This study tested a new medicine called NNC-0156-0000-0009 (also known as nonacog beta pegol) in 25 children with hemophilia B, a bleeding disorder. The goal was to see if the drug is safe, helps prevent bleeding episodes, and how the body processes it. Children received the drug…

This study tested a new medicine called NNC6019-0001 in 105 adults with a heart condition caused by abnormal protein buildup (ATTR cardiomyopathy). Participants received either the medicine or a placebo by infusion every 4 weeks for about 64 weeks. The goal was to see if the medi…

This study tested a new medicine, somapacitan, given once a week against the standard daily medicine Norditropin in 110 Chinese children with growth hormone deficiency. The goal was to see if the weekly shot works as well as the daily one for helping children grow. Children were …

This study followed 291 adults with type 2 diabetes whose blood sugar was not well controlled on their current medication (DPP4i). Participants switched to an oral version of semaglutide, a drug that helps lower blood sugar and may aid weight loss. Over about 5-6 months, research…

This study tested a new medicine called Mim8 in 70 children aged 1-11 with hemophilia A, some of whom had inhibitors that make standard treatments less effective. Mim8 is given as a shot under the skin to prevent bleeding episodes. The study lasted about 54-98 weeks and tracked s…

This study tested whether a weekly injection of semaglutide (a medicine also used for weight loss) can improve daily life and reduce symptoms in people with obesity-related heart failure. About 529 adults with a BMI of 30 or higher and heart failure with preserved ejection fracti…

This study looked at a new fast-acting insulin (NNC0471-0119) given through an insulin pump in 65 adults with type 2 diabetes. Researchers measured how quickly the insulin entered the bloodstream and lowered blood sugar, comparing it to a standard insulin called aspart. The goal …

This study looked at how people with type 1 or type 2 diabetes felt about using the DuraTouch® device. Over 12 weeks, 128 participants rated how easy, convenient, and satisfying the device was to use. The goal was to see if the device makes daily diabetes care simpler and more co…

This study looked at whether a weekly injection of semaglutide can improve daily life and reduce symptoms in people with obesity-related heart failure and type 2 diabetes. About 617 adults took part, receiving either the drug or a dummy shot for about a year. Researchers measured…

This study tested whether semaglutide, a diabetes medicine, improves walking ability in people with type 2 diabetes and peripheral artery disease (narrowed leg arteries). About 792 adults received weekly injections of semaglutide or a placebo for 59 weeks. The main goal was to se…

This early-stage study tested a new medicine called NNC0662-0419 in 100 adults with overweight or obesity. The goal was to see if it is safe and how the body handles it. Participants received either the study drug or a placebo as an injection under the skin. The study lasted abou…

This study tested whether CagriSema, a combination of two drugs, can reduce how much people with overweight or obesity eat and their appetite. 62 participants received either CagriSema or a placebo for about 32 weeks. Researchers measured food intake and stomach emptying to see i…

This study tested a weekly injection of semaglutide (2.4 mg) versus a placebo in 407 adults with obesity and knee osteoarthritis. The goal was to see if the drug helps with weight loss and reduces knee pain. Participants also received diet and exercise advice. The trial lasted ab…

This study tested a new medicine called CagriSema (a mix of two drugs) in 164 adults with overweight or obesity. It measured how the drug changes appetite, food intake, and brain activity compared to a placebo or no medicine. The goal is to understand how CagriSema helps control …

This study tested a new insulin called insulin icodec in 18 children and teenagers (ages 10 to 17) with type 2 diabetes. Each participant received a single injection based on their body weight, and researchers measured how the insulin moved through their blood over time. The goal…

This study watched 23 people with hemophilia A who were already using Esperoct as part of their normal care. Researchers tracked side effects and how well the medicine worked over about two years. The goal was to confirm the drug's safety and effectiveness in everyday use, not to…

This study tested a new formulation of the medicine semaglutide in healthy adults. The goal was to measure how much semaglutide gets into the blood from the new tablet compared to the current tablet. About 264 participants took different doses for up to 21 weeks, with blood sampl…

This early-stage study tested a single dose of the experimental medicine NNC0662-0419 in 100 adults with overweight or obesity. Participants were Japanese, Chinese, or non-Asian to see how the drug behaves in different ethnic groups. The main goals were to measure drug levels in …

This study looked at how a new medicine for type 2 diabetes, called NNC0519-0130, is processed in the body when people have different levels of kidney function. 36 adults with normal, mildly, moderately, or severely reduced kidney function received a single dose. Researchers meas…

This study used online questionnaires to understand how well healthcare providers and people with or at risk for MASH (a liver disease) understand the links between MASH and heart, kidney, and metabolic conditions. About 1,330 participants completed the 25-minute survey. The goal…

This study looked at how well doctors can catch serious and non-serious side effects of the weight-loss drug Saxenda in Mexican patients. It involved 27 adults with obesity who were already prescribed the drug by their own doctor. The main goal was to track cases of pancreatitis …

This study looked at 40 adults with overweight or obesity to see if giving two weight-loss medicines (cagrilintide and semaglutide) together in one injection works the same as giving them separately. Participants received weekly shots for 22 weeks, and researchers measured medici…

This study follows people who were in the SELECT trial to see how their health changes over the next 10 years. No new medicine is given—participants just fill out a health questionnaire every 6 months. The goal is to learn about long-term effects like heart attacks, cancer, weigh…

This study analyzed health records from nearly 195,000 people in Denmark, Sweden, and Norway to see if semaglutide (the drug in Ozempic and Rybelsus) is linked to a higher risk of pancreatic cancer. Researchers compared new users of semaglutide to new users of other diabetes medi…

This study looked at whether a new diabetes medicine (NNC0519-0130) changes how the body processes a common birth control pill. It also checked if the drug affects how fast the stomach empties. The study involved 47 healthy women past menopause and lasted about 35 weeks. Results …

This completed study surveyed 608 heart and kidney doctors to understand their awareness and use of a blood test called hsCRP, which measures inflammation. The goal was to learn what doctors think about inflammation's role in treating patients with heart disease, kidney disease, …

This study tested a new medicine called Inno8 in 95 healthy men to see if it is safe. The medicine is being developed for people with hemophilia A, a bleeding disorder. Participants received either Inno8 or a placebo by injection or as a tablet. The study is complete and will hel…

This study looked at how common weight-related health problems are in people of different weights in India, Pakistan, Philippines, and Vietnam. Researchers tracked 1,170 adults over about 2 years to see how often these problems occur. Participants did not receive any treatment as…

This study tested whether a new medicine called etavopivat, being developed for sickle cell disease, affects the heart's electrical activity. Thirty-three healthy adults received different doses of the drug, a placebo, or an approved heart medication. The goal was to check for an…

This study examined how often adults with obesity in the Gulf region have related health issues like diabetes, high blood pressure, and fatty liver disease. Researchers also looked at the medical costs and healthcare use over one year. The study involved 1,316 adults and used med…

This study looked at how a new insulin (NNC0363-1063) interacts with a non-glucose carbohydrate (a type of sugar not used for energy) in 36 adults with type 1 diabetes. Participants received a fixed dose of the insulin and different amounts of the carbohydrate in random order ove…

This study tested a single dose of the experimental medicine etavopivat in 24 healthy Chinese adults. Researchers measured how the drug moves through the body and checked for side effects over about a week. The goal was to gather safety and dosing information before testing in pa…

This study looked at how semaglutide, a diabetes medicine, affects the kidneys in people with type 2 diabetes and chronic kidney disease. 106 participants received either semaglutide or a placebo injection once a week for about a year. Researchers used MRI scans, blood and urine …

This early-stage study tested a new oral medicine, NNC0705-0001, in 116 healthy adults to see if it is safe and how the body handles it. The drug is being developed to treat chronic inflammation, which can lead to heart and metabolic diseases. Participants received either the dru…

This study looked at how the liver affects the body's processing of cagrilintide, a drug being developed for weight management. It involved 32 participants with different levels of liver function and healthy volunteers. The goal was to measure drug levels in the blood, not to tre…

This study tested a single injection of a new drug, NNC0582-0001, in 56 healthy adults to see if it is safe and how the body processes it. Participants received either the drug or a placebo and were monitored for a year. The goal was to gather early safety and drug-level informat…

This study tested whether a new medicine called etavopivat changes how the body processes five common drugs: digoxin, rosuvastatin, pitavastatin, metformin, and midazolam. Thirty-seven healthy adults took etavopivat daily for 10 days along with single doses of each common drug. T…

This study tested two different versions (a tablet and a capsule) of an experimental medicine called NDec, which is being developed for sickle cell disease. 44 healthy adults each took a single dose of both forms to see how the body absorbs them. The goal was to compare the two f…

This study looked at how a single injection of the experimental drug NNC0194-0499 behaves in people with different levels of liver function, from healthy to severely impaired. The drug is being developed for non-alcoholic fatty liver disease (NAFLD) and its more serious form, NAS…

This study looked at how a high-fat meal changes the amount of etavopivat in the blood of 16 healthy adults. Each person took the drug once after eating and once on an empty stomach. The goal was to see if food affects drug levels, which helps guide future dosing for people with …

This study gathered information from 1,061 adults in Saudi Arabia about their weight, blood sugar, heart health, and lifestyle. The goal was to understand how common heart disease is in people with obesity. Participants filled out a questionnaire during a routine doctor visit, an…

This early-stage study tested a new medicine, NNC0650-0013, which may one day treat type 2 diabetes. Eleven healthy men received a single injection of the drug or a placebo to check for safety and how the body processes it. The study lasted 11 to 17 weeks and required some overni…

This early-stage study tested a new experimental drug, NNC0113-6856, in 70 healthy men to see if it is safe and how the body processes it. Participants received either a single oral dose or an injection into the vein. The goal was to gather initial safety data and measure drug le…

This study tested whether a new pen injector delivers the drug Mim8 into the blood as well as a standard syringe and cartridge. 205 healthy men received a single injection of Mim8 using either the pen or the syringe. The goal was to see if the pen works just as well, making it ea…

This early-stage study tested a new medicine, NNC0581-0001, in 48 healthy adults and people with fatty liver (hepatic steatosis). The main goal was to check safety and how the drug moves through the body after a single injection. Participants were randomly assigned to receive the…

This study surveyed 1,500 Chinese heart and kidney specialists to understand their awareness and perceptions of systemic inflammation in patients with both atherosclerotic cardiovascular disease and chronic kidney disease. The goal was to learn how doctors currently identify and …

This study looked at how different amounts of water and delays before breakfast affect levels of a new semaglutide tablet in the blood. It involved 121 healthy men who took the tablet daily for 10 days. The goal was to find the best way to take the medicine for future use.

This completed Phase 1 study tested two different versions of the experimental drug NNC0519-0130 in 46 adults with overweight or obesity. The main goal was to measure how much of the drug gets into the blood and compare the two formulations. Participants received both versions by…

This study tested a single dose of an experimental drug called etavopivat in 48 adults with mild, moderate, or severe liver problems, as well as those with healthy livers. The goal was to see how the liver affects the drug's levels in the body and to check for safety. Participant…

This study tested a single dose of the experimental drug monlunabant in 73 healthy men of normal weight, half of Japanese descent and half of Caucasian descent. The main goal was to check for side effects and see how the drug moves through the body. Participants were randomly ass…

This study tested how different versions of the experimental drug ziltivekimab move through the body when given as a single injection under the skin. It compared two different formulas and two injection methods: a manual syringe and a pen-injector. The study involved 267 healthy …

This study tested four different tablet versions of the medicine semaglutide in 90 healthy men. The goal was to see how each tablet is absorbed into the body, not to treat any disease. Participants were randomly assigned to receive one of the tablet versions, and the study lasted…

This study tested whether health data can be collected remotely from adults with overweight or obesity using a smartphone app and connected devices like a watch and scale. 146 participants took part for 24 weeks without any study medicine. The goal was to learn how to run future …

This study looked at how CagriSema, a drug for obesity, affects the levels of two common medicines (atorvastatin and warfarin) in the blood. 34 adults with overweight or obesity took part. The goal was to check for drug interactions, not to treat obesity. Results help doctors und…

This study looked at how many people with heart and/or kidney disease in the Middle East have high levels of body-wide inflammation. Researchers collected medical information from 756 adults during a single clinic visit. No treatments or medications were given as part of this stu…

This study looked at health data from over 550,000 Chinese adults to see how being overweight or obese relates to heart disease. Researchers used national survey information to track how common heart conditions are and how they change over time. No treatments were given—this was …